Literature DB >> 7051232

Synergistic combinations of antibiotics in gram-negative bacillary infections.

J Klastersky, S H Zinner.   

Abstract

In vitro synergy (or at least an additive effect between antibiotics in vitro) is likely to have clinical significance. Data in the literature strongly suggest that, in patients who lack the natural mechanisms of defense against infection, better clinical results can be achieved by treatment with two drugs to which the pathogenic organism is sensitive rather than only one. Moreover, there is some evidence that the use of antibiotic combinations found to be synergistic in vitro is associated with a better clinical outcome in patients with decreased mechanisms of defense against infection, especially neutropenia. The use of synergistic drug combinations should be continued as empirical therapy in severely neutropenic or otherwise compromised patients, especially in those with malignant tumors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7051232     DOI: 10.1093/clinids/4.2.294

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  41 in total

Review 1.  Empiric treatment of infection during granulocytopenia: a comprehensive approach.

Authors:  J Klastersky
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

Review 2.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

3.  Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa.

Authors:  P Van der Auwera; J Klastersky; H Lagast; M Husson
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

4.  In vitro activity of aztreonam, cefotaxime, ceftazidime and imipenem combined with ciprofloxacin against gram-negative bacilli and compared with amikacin combinations against Pseudomonas aeruginosa.

Authors:  M Díez Enciso
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

5.  Activity of cefotiam in combination with beta-lactam antibiotics on enterobacterial hospital strains.

Authors:  R Vanhoof; J M Hubrechts; H J Nyssen; E Nulens; J Leger; N de Schepper; E Kupperberg; M L Couvreur
Journal:  Pharm Weekbl Sci       Date:  1990-06-22

6.  Comparison of antimicrobial efficacy of a fixed dose combination of ceftazidime + sulbactam with ceftazidime and sulbactam alone against five bacteria.

Authors:  S M Shrivastava; S K Shukla; M Chaudhary
Journal:  Folia Microbiol (Praha)       Date:  2009-11-24       Impact factor: 2.099

7.  Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.

Authors:  F Brunet; G Vedel; F Dreyfus; J F Vaxelaire; T Giraud; B Schremmer; J F Monsallier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

Review 8.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

9.  Comparative study of the serum bactericidal activity of cefoperazone alone and in combination with amikacin or mezlocillin against gram-negative bacilli and Staphylococcus aureus.

Authors:  H Lagast; J Klastersky; H Standiford; A Viollier
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

10.  Serum bactericidal activity of aztreonam, cefoperazone, and amikacin, alone or in combination, against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa.

Authors:  Y Van Laethem; M Husson; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.